Anitra Fielding

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

Ayala Hubert, Gillian Mitchell, Rita K Schmutzler, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

James X. Sun, Roman Yelensky, Zhongwu Lai, 2017, Oncotarget.

Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy

Werner Meier, Ignace Vergote, Philipp Harter, 2016, Cancer.